CRISPR Therapeutics AG $CRSP Shares Bought by Nordea Investment Management AB

Nordea Investment Management AB grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 0.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 127,500 shares of the company’s stock after purchasing an additional 900 shares during the period. Nordea Investment Management AB owned 0.15% of CRISPR Therapeutics worth $6,249,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Axxcess Wealth Management LLC boosted its stake in shares of CRISPR Therapeutics by 12.0% during the 2nd quarter. Axxcess Wealth Management LLC now owns 11,550 shares of the company’s stock worth $562,000 after purchasing an additional 1,241 shares during the last quarter. Moran Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $664,000. Alpine Woods Capital Investors LLC boosted its stake in shares of CRISPR Therapeutics by 27.8% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 8,501 shares of the company’s stock worth $413,000 after purchasing an additional 1,851 shares during the last quarter. Concurrent Investment Advisors LLC acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $1,117,000. Finally, IFP Advisors Inc boosted its position in shares of CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock worth $45,000 after acquiring an additional 181 shares during the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CRSP has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of CRISPR Therapeutics in a report on Thursday, September 18th. They issued an “overweight” rating and a $70.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday, June 27th. Zacks Research upgraded shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a report on Monday, October 13th. Finally, HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, September 23rd. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $72.59.

CRISPR Therapeutics Stock Up 7.0%

Shares of CRSP stock opened at $73.97 on Tuesday. The stock has a market cap of $6.73 billion, a price-to-earnings ratio of -13.62 and a beta of 1.84. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm’s 50 day moving average price is $60.81 and its two-hundred day moving average price is $50.52.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics’s revenue was up 72.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.49) earnings per share. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The shares were sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares of the company’s stock, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares in the company, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,213 shares of company stock worth $3,810,458. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.